Engineering strategies and binding mechanisms of therapeutic anti–PD-1 antibodies approved by regulatory agencies globally
- DOI
- 10.3389/fimmu.2026.1834585
- Published
- 2026-05-21
- Container
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1834585,
title = {Engineering strategies and binding mechanisms of therapeutic anti–PD-1 antibodies approved by regulatory agencies globally},
author = {Juan C. Almagro and Keyla Gómez-Castellano and Ileana Licona-Limón and Gregorio de Jesús Carballo Uicab and Frida D. Ramírez-Villedas and Alejandra Montes-Luna and Edith González-González and Silvia Godínez-Palma and Hugo A. Barrera Saldaña and Sonia M. Pérez-Tapia},
year = {2026},
journal = {Frontiers in Immunology},
doi = {10.3389/fimmu.2026.1834585},
url = {https://doi.org/10.3389/fimmu.2026.1834585}
}RIS
TY - JOUR TI - Engineering strategies and binding mechanisms of therapeutic anti–PD-1 antibodies approved by regulatory agencies globally AU - Juan C. Almagro AU - Keyla Gómez-Castellano AU - Ileana Licona-Limón AU - Gregorio de Jesús Carballo Uicab AU - Frida D. Ramírez-Villedas AU - Alejandra Montes-Luna AU - Edith González-González AU - Silvia Godínez-Palma AU - Hugo A. Barrera Saldaña AU - Sonia M. Pérez-Tapia PY - 2026 JO - Frontiers in Immunology DO - 10.3389/fimmu.2026.1834585 UR - https://doi.org/10.3389/fimmu.2026.1834585 ER -
APA
Almagro, J. C., Gómez-Castellano, K., Licona-Limón, I., Uicab, G. D. J. C., Ramírez-Villedas, F. D., Montes-Luna, A., González-González, E., Godínez-Palma, S., Saldaña, H. A. B., & Pérez-Tapia, S. M. (2026). Engineering strategies and binding mechanisms of therapeutic anti–PD-1 antibodies approved by regulatory agencies globally. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1834585
Source records
- crossref · retrieved 2026-09-26T18:45:58.975Z